Sandra Chaparro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sandra Chaparro has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
Javier Jimenez
Miami Cardiac and Vascular Institute, Baptist Health South Florida
5 shared publicationsAnshul Saxena
Miami Cardiac and Vascular Institute, Baptist Health South Florida
4 shared publicationsMuni Rubens
Miami Cardiac and Vascular Institute, Baptist Health South Florida
3 shared publications- Muni Rubens
Herbert Wertheim College of Medicine Florida International University Miami Florida USA
3 shared publications Venkataraghavan Ramamoorthy
Baptist Health South Florida, Miami, Florida 33176, USA
3 shared publicationsAmit Badiye
2 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Elsevier in Journal of Cardiac Failure
Long-Term Adherence and Outcomes in Ambulatory Heart Failure Patients Using the Cordella Pulmonary Artery Sensor System
- 9 November 2026
- Published by Elsevier in Journal of Cardiac Failure
Open AccessLong-Term Adherence and Outcomes in Ambulatory Heart Failure Patients Using the Cordella Pulmonary Artery Sensor System
- 14 August 2026
- Published by Springer Nature
- p. 1-16
Heart Failure
- 24 June 2025
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 37 (1) , 18-24
Association between pulse wave velocity and coronary atherosclerosis
Background: Pulse wave velocity (PWV) is considered a more direct and accurate measure of arterial stiffness. This study explored the relationship between PWV and the presence and severity of coronary artery calcification (CAC) and coronary artery plaque (CAP). Methods: The current study was a cross-sectional analysis of data from the Miami Heart Study (MiHeart). The primary outcome variable of this study was the CAC score. The secondary outcome was the presence of CAC and CAP. Multivariable logistic regression and Bayesian linear regression were used to find the association between PWV CAC and CAP. Results: A total of 2359 participants were included in the study. The mean age (SD) of the sample was 53.4 (6.8) years and 50.4% were men. Multivariable logistic regression analysis showed that the odds of having CAC greater than 0 was significantly higher with increasing PWV [odds ratio (OR): 1.09, 95% confidence interval (CI): 1.01–1.18]. Similarly, multivariable logistic regression analysis also showed that the odds for CAP were significantly higher with increasing PWV (OR: 1.14, 95% CI: 1.06–1.23). The results of Bayesian linear regression analysis showed that there was a significant association between PWV and log CAC score. Conclusion: In a large sample of participants from the community and without a history of known cardiovascular disorder, we found that an increase in PWV was associated with the presence of CAC and CAP. In addition, we also found that PWV was associated with severity of CAC as well. Our findings show that PWV could be an important marker of subclinical coronary atherosclerosis in the general population.
- 24 June 2025
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 37 (1) , 18-24
Association between pulse wave velocity and coronary atherosclerosis
Background: Pulse wave velocity (PWV) is considered a more direct and accurate measure of arterial stiffness. This study explored the relationship between PWV and the presence and severity of coronary artery calcification (CAC) and coronary artery plaque (CAP). Methods: The current study was a cross-sectional analysis of data from the Miami Heart Study (MiHeart). The primary outcome variable of this study was the CAC score. The secondary outcome was the presence of CAC and CAP. Multivariable logistic regression and Bayesian linear regression were used to find the association between PWV CAC and CAP. Results: A total of 2359 participants were included in the study. The mean age (SD) of the sample was 53.4 (6.8) years and 50.4% were men. Multivariable logistic regression analysis showed that the odds of having CAC greater than 0 was significantly higher with increasing PWV [odds ratio (OR): 1.09, 95% confidence interval (CI): 1.01–1.18]. Similarly, multivariable logistic regression analysis also showed that the odds for CAP were significantly higher with increasing PWV (OR: 1.14, 95% CI: 1.06–1.23). The results of Bayesian linear regression analysis showed that there was a significant association between PWV and log CAC score. Conclusion: In a large sample of participants from the community and without a history of known cardiovascular disorder, we found that an increase in PWV was associated with the presence of CAC and CAP. In addition, we also found that PWV was associated with severity of CAC as well. Our findings show that PWV could be an important marker of subclinical coronary atherosclerosis in the general population.
- 1 April 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (2) , e004946
Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study
BACKGROUND: Whether prolonged and excessive alcohol consumption contributes to dilated cardiomyopathy (DCM) remains uncertain. This study aimed to describe the prevalence of alcohol use in patients with DCM and their first-degree relatives (FDRs) and determine if cumulative alcohol exposure associates with DCM/partial DCM or modifies the association of DCM with DCM-relevant rare variants. METHODS: All probands had DCM; FDRs were classified as with or without DCM or partial DCM. Alcohol exposure was measured with the Alcohol Use Disorder Identification Test-Consumption questionnaire and years of drinking. Rare variants in 36 DCM genes were classified as pathogenic, likely pathogenic, or variants of uncertain significance (pathogenic, likely pathogenic, variant of uncertain significance). Generalized linear mixed models were used to assess the association of DCM/partial DCM with alcohol use among FDRs. RESULTS: DCM/partial DCM was found in 21.8% of 1373 FDRs of 1148 DCM probands. The prevalence of former or current alcohol use was 68% for probands and 70% for FDRs. About 30% of probands and 37% of FDRs had positive Alcohol Use Disorder Identification Test-Consumption scores, indicating moderate or heavy drinking. Among FDRs, DCM/partial DCM was associated with the presence of pathogenic/likely pathogenic variants in DCM genes (odds ratio, 3.51 [95% CI, 2.33–5.29]) but not with alcohol exposure. Cumulative alcohol exposure was not found to modify the association between DCM/partial DCM and these variants ( P =0.55). CONCLUSIONS: Alcohol use was frequent among probands and FDRs. This study did not provide evidence supporting an association of cumulative alcohol exposure with DCM/partial DCM or a modifying effect of alcohol use on the association of DCM with DCM-relevant rare variants. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03037632.
- 1 April 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (2) , e004946
Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study
BACKGROUND: Whether prolonged and excessive alcohol consumption contributes to dilated cardiomyopathy (DCM) remains uncertain. This study aimed to describe the prevalence of alcohol use in patients with DCM and their first-degree relatives (FDRs) and determine if cumulative alcohol exposure associates with DCM/partial DCM or modifies the association of DCM with DCM-relevant rare variants. METHODS: All probands had DCM; FDRs were classified as with or without DCM or partial DCM. Alcohol exposure was measured with the Alcohol Use Disorder Identification Test-Consumption questionnaire and years of drinking. Rare variants in 36 DCM genes were classified as pathogenic, likely pathogenic, or variants of uncertain significance (pathogenic, likely pathogenic, variant of uncertain significance). Generalized linear mixed models were used to assess the association of DCM/partial DCM with alcohol use among FDRs. RESULTS: DCM/partial DCM was found in 21.8% of 1373 FDRs of 1148 DCM probands. The prevalence of former or current alcohol use was 68% for probands and 70% for FDRs. About 30% of probands and 37% of FDRs had positive Alcohol Use Disorder Identification Test-Consumption scores, indicating moderate or heavy drinking. Among FDRs, DCM/partial DCM was associated with the presence of pathogenic/likely pathogenic variants in DCM genes (odds ratio, 3.51 [95% CI, 2.33–5.29]) but not with alcohol exposure. Cumulative alcohol exposure was not found to modify the association between DCM/partial DCM and these variants ( P =0.55). CONCLUSIONS: Alcohol use was frequent among probands and FDRs. This study did not provide evidence supporting an association of cumulative alcohol exposure with DCM/partial DCM or a modifying effect of alcohol use on the association of DCM with DCM-relevant rare variants. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03037632.
- 16 October 2024
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 32 (6)
Prevalence and Association of Deep Vein Thrombosis on Clinical Outcomes Among COVID-19 Patients
Background: Studies have shown that COVID-19 could lead coagulation defects, resulting in increased morbidity and mortality. In this study, we sought to estimate the prevalence of deep vein thrombosis (DVT) among COVID-19 hospitalizations and its effects on hospital outcomes using a large administrative database. Methods: We conducted a retrospective analysis of the 2020 California State Inpatient Database. All hospitalizations ≥18 years and primary diagnosis of COVID-19 were included and were stratified into those with and without DVT. The main outcomes of the study were in-hospital mortality, prolonged length of stay, vasopressor use, mechanical ventilation, and intensive care unit admission. Results: We included a total of 94,114 primary COVID-19 hospitalizations for the analysis. Among them, 1575 (1.7%) had DVT. After adjusting for covariates, regression analysis showed that those with DVT had significantly greater odds for mortality (adjusted odds ratio [aOR], 2.34; 95% confidence interval [CI], 2.07–2.65), prolonged length of stay (aOR, 3.51; 95% CI, 3.16–3.91), vasopressor use (aOR, 4.23; 95% CI, 3.78–4.74), mechanical ventilation (aOR, 2.90; 95% CI, 2.38–3.53), and intensive care unit admission (aOR, 4.32; 95% CI, 3.85–4.84). Conclusions: In our cohort, though only a few COVID-19 hospitalizations had DVT, the risk for adverse outcome was significantly higher. Therefore, healthcare providers should promptly monitor for DVT among COVID-19 patients and manage it promptly.
- 16 October 2024
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 32 (6)
Prevalence and Association of Deep Vein Thrombosis on Clinical Outcomes Among COVID-19 Patients
Background: Studies have shown that COVID-19 could lead coagulation defects, resulting in increased morbidity and mortality. In this study, we sought to estimate the prevalence of deep vein thrombosis (DVT) among COVID-19 hospitalizations and its effects on hospital outcomes using a large administrative database. Methods: We conducted a retrospective analysis of the 2020 California State Inpatient Database. All hospitalizations ≥18 years and primary diagnosis of COVID-19 were included and were stratified into those with and without DVT. The main outcomes of the study were in-hospital mortality, prolonged length of stay, vasopressor use, mechanical ventilation, and intensive care unit admission. Results: We included a total of 94,114 primary COVID-19 hospitalizations for the analysis. Among them, 1575 (1.7%) had DVT. After adjusting for covariates, regression analysis showed that those with DVT had significantly greater odds for mortality (adjusted odds ratio [aOR], 2.34; 95% confidence interval [CI], 2.07–2.65), prolonged length of stay (aOR, 3.51; 95% CI, 3.16–3.91), vasopressor use (aOR, 4.23; 95% CI, 3.78–4.74), mechanical ventilation (aOR, 2.90; 95% CI, 2.38–3.53), and intensive care unit admission (aOR, 4.32; 95% CI, 3.85–4.84). Conclusions: In our cohort, though only a few COVID-19 hospitalizations had DVT, the risk for adverse outcome was significantly higher. Therefore, healthcare providers should promptly monitor for DVT among COVID-19 patients and manage it promptly.
- 17 September 2024
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 33 (11) , 108016
Frailty among stroke patients and its effects on hospital outcomes
- 17 September 2024
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 33 (11) , 108016
Frailty among stroke patients and its effects on hospital outcomes
- 30 November 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 212, 67-72
Hospital Outcomes in Patients With Pulmonary Hypertension With Atrial Fibrillation in the United States
- 30 November 2023
- Published by Elsevier in The American Journal of Cardiology
- Vol. 212, 67-72
Hospital Outcomes in Patients With Pulmonary Hypertension With Atrial Fibrillation in the United States
- 8 September 2023
- Published by Wiley
- p. 233-246
LVADVersus Cardiac Transplantation: When to List? When to Implant?
- 8 September 2023
- Published by Wiley
- p. 233-246
LVADVersus Cardiac Transplantation: When to List? When to Implant?
- 17 September 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 183, 109-114
Hospital Outcomes Among COVID-19 Hospitalizations With Myocarditis from the California State Inpatient Database
- 17 September 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 183, 109-114
Hospital Outcomes Among COVID-19 Hospitalizations With Myocarditis from the California State Inpatient Database
- 1 January 2022
- Published by Springer Nature
- p. 1101-1115
Heart Failure